MARKET DEFINITION
Lung cancer screening is a process that's used to detect the presence of lung cancer in healthy people as well as people with a high risk of lung cancer. The goal of the Lung Cancer Screening Program is to identify lung cancer early, when it is most treatable, by screening and keeping track of those who are most at risk, particularly smokers. The solution offers a wide range of features such as patient identification, enrollment, and eligibility tracking, reporting, data integration and analytics, and patient communication. Thus, the demand for this software is increasing in hospitals and radiological facilities.
MARKET DYNAMICS
The second most frequent type of cancer is a small cell and non-small cell lung cancer. A very small percentage of lung cancer diagnoses occur in patients under the age of 45, with most patients being 65 or older. With approximately 25% of all cancer fatalities being caused by lung cancer, it is by far the most common type of cancer. Lung cancer claims more lives each year than colon, breast, and prostate cancers combined. Moreover, in 2019, there were 703 million people worldwide who were 65 or older. According to projections, there will be 1.5 billion elderly people worldwide in 2050. Thus, the rising aging population is expected to increase the chances of cancer. On the other hand, efficiency issues with the software are expected to hamper the market. However, AI integration along with rising trends of digitalization in healthcare is projected to create lucrative opportunities for the software market in the coming years.
REPORT SCOPE
The report titled “Global Lung Cancer Screening Software Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Lung Cancer Screening Software market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Lung Cancer Screening Software market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Lung Cancer Screening Software Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.
GEOGRAPHICAL OVERVIEW
The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION
The Global Lung Cancer Screening Software Market is segmented based on offering, deployment, application, end-user, and region. Based on offering, the market has been segmented into Software, and Services. Software is further bifurcated into Standalone, Integrated. Based on deployment, the market comprises Cloud and On-Premises. Based on application, the market has been segmented into Database Management, Reporting & Analytics, and Others, whereas, the end-user segmentation includes Oncology Centers, Hospitals, and Others.
COMPETITION LANDSCAPE
The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Lung Cancer Screening Software market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Lung Cancer Screening Software market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Lung Cancer Screening Software market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Lung Cancer Screening Software industry in the past three years.
Key players in the Global Lung Cancer Screening Software Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:
· Koninklijke Philips N.V.
· Siemens Healthineers AG
· Thynk Health platform
· Eon
· Medtronic
· Nuance Communications, Inc.
· Volpara Health Limited
· PenLung Solution
· Magview
· Others
COVID-19 IMPACT ANALYSIS ON GLOBAL LUNG CANCER SCREENING SOFTWARE MARKET
The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.
In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as the broader market, thereby, providing accurate and trustworthy forecasts.
Report Attribute/Metric
|
Details
|
Market Size
|
In USD Million
|
CAGR
|
In % (2022-2028)
|
Base Year
|
2021
|
Forecast Period
|
2022 – 2028
|
Historical Data
|
2017 to 2021
|
Forecast Unit
|
Value (US$ Mn)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors and Trends
|
Geographies Covered
|
North America, Europe, Asia-Pacific, South America, and Middle East & Africa
|
Key Players Analyzed
|
Koninklijke Philips N.V., Siemens Healthineers AG, Thynk Health platform, Eon, Medtronic, Nuance Communications, Inc., Volpara Health Limited, PenLung Solution, Magview, and Others
|
Customization & Pricing
|
Available on Request (10% Customization is Free)
|
RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED
1. What is the current size of the global Lung Cancer Screening Software market?
2. What will be the growth rate of the market over the forecast period?
3. Who are the key manufacturers/vendors in the Lung Cancer Screening Software market space?
4. What are the major market opportunities and market risks faced by the market?
5. What is the impact of COVID-19 on the market?
6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
7. What are the key outcomes of Porter's five forces model?
8. Who are the distributors, traders, and vendors in the industry?
REASONS FOR BUYING THIS REPORT:
· The report offers comprehensive data on the Lung Cancer Screening Software market elaborating on the current state and future growth prospects both globally and regionally
· It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
· The report offers deep-dive insights into each market segment and critical factors responsible for its growth
· The report presents a precise picture of the dynamic competitive landscape which helps our client advance their market position
· The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
· Cross-segment country-level analysis is included in the report which provides granular analysis of more than 20+ countries covered in the report's scope
· The study includes detailed profiles of major manufacturers to help our readers gain a holistic overview of the market competitors and consequently align their business strategies
Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Application
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Offering Trends
3.2.2. Deployment Trends
3.2.3. Application Trends
3.2.4. End-user Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Lung Cancer Screening Software Market
3.6. COVID-19 Impact Assessment in Lung Cancer Screening Software Market
3.6.1. Impact Assessment on Global Lung Cancer Screening Software Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape
Chapter 4. Global Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
4.1. Global Lung Cancer Screening Software Market Share, By Offering, 2017 - 2028 (USD Million)
4.1.1. Software
4.1.1.1. Standalone
4.1.1.2. Integrated
4.1.2. Services
Chapter 5. Global Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
5.1. Global Lung Cancer Screening Software Market Share, By Deployment, 2017 - 2028 (USD Million)
5.1.1. Cloud
5.1.2. On-Premise
Chapter 6. Global Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
6.1. Global Lung Cancer Screening Software Market Share, By Application, 2017 - 2028 (USD Million)
6.1.1. Database Management
6.1.2. Reporting & Analytics
6.1.3. Others
Chapter 7. Global Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
7.1. Global Lung Cancer Screening Software Market Share, By End-user, 2017 - 2028 (USD Million)
7.1.1. Oncology Centers
7.1.2. Hospitals
7.1.3. Others
Chapter 8. Global Lung Cancer Screening Software Market Overview, By Geography, 2017 - 2028 (USD Million)
8.1. Global Lung Cancer Screening Software Market Share, By Geography, 2017 - 2028 (USD Million)
8.1.1. Market Deployment and Projections, by Countries, 2017 - 2028 (USD Million)
8.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)
Chapter 9. North America Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. North America Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market Deployment and projections, 2017 - 2028 (USD Million)
9.1.2. North America Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
9.1.3. North America Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
9.1.4. North America Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
9.1.5. North America Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2. North America Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. U.S. Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. U.S. Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
9.2.1.2. U.S. Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
9.2.1.3. U.S. Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.1.4. U.S. Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.2. Canada Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. Canada Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
9.2.2.2. Canada Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
9.2.2.3. Canada Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.2.4. Canada Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.3. Mexico Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. Mexico Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
9.2.3.2. Mexico Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
9.2.3.3. Mexico Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.3.4. Mexico Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
Chapter 10. Europe Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. Europe Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market Deployment and projections, 2017 - 2028 (USD Million)
10.1.2. Europe Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
10.1.3. Europe Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
10.1.4. Europe Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
10.1.5. Europe Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2. Europe Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. Germany Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. Germany Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
10.2.1.2. Germany Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
10.2.1.3. Germany Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.1.4. Germany Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.2. France Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. France Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
10.2.2.2. France Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
10.2.2.3. France Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.2.4. France Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.3. UK Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. UK Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
10.2.3.2. UK Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
10.2.3.3. UK Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.3.4. UK Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.4. Italy Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
10.2.4.1. Italy Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
10.2.4.2. Italy Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
10.2.4.3. Italy Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.4.4. Italy Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.5. Spain Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
10.2.5.1. Spain Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
10.2.5.2. Spain Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
10.2.5.3. Spain Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.5.4. Spain Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.6. NORDIC Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
10.2.6.1. NORDIC Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
10.2.6.2. NORDIC Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
10.2.6.3. NORDIC Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.6.4. NORDIC Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.7. Russia and CIS Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
10.2.7.1. Russia and CIS Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
10.2.7.2. Russia and CIS Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
10.2.7.3. Russia and CIS Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.7.4. Russia and CIS Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.8. Rest of Europe Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
10.2.8.1. Rest of Europe Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
10.2.8.2. Rest of Europe Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
10.2.8.3. Rest of Europe Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.8.4. Rest of Europe Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
Chapter 11. Asia Pacific Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. Asia Pacific Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market Deployment and projections, 2017 - 2028 (USD Million)
11.1.2. Asia Pacific Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
11.1.3. Asia Pacific Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
11.1.4. Asia Pacific Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
11.1.5. Asia Pacific Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2. Asia Pacific Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. India Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. India Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
11.2.1.2. India Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
11.2.1.3. India Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.1.4. India Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.2. China Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. China Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
11.2.2.2. China Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
11.2.2.3. China Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.2.4. China Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.3. Japan Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Japan Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
11.2.3.2. Japan Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
11.2.3.3. Japan Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.3.4. Japan Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.4. ASEAN Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
11.2.4.1. ASEAN Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
11.2.4.2. ASEAN Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
11.2.4.3. ASEAN Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.4.4. ASEAN Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.5. South Korea Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
11.2.5.1. South Korea Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
11.2.5.2. South Korea Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
11.2.5.3. South Korea Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.5.4. South Korea Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.6. Australia Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
11.2.6.1. Australia Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
11.2.6.2. Australia Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
11.2.6.3. Australia Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.6.4. Australia Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.7. Rest of Asia Pacific Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
11.2.7.1. Rest of Asia Pacific Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
11.2.7.2. Rest of Asia Pacific Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
11.2.7.3. Rest of Asia Pacific Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.7.4. Rest of Asia Pacific Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
Chapter 12. South America Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
12.1. South America Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
12.1.1. Market Deployment and projections, 2017 - 2028 (USD Million)
12.1.2. South America Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
12.1.3. South America Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
12.1.4. South America Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
12.1.5. South America Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
12.2. South America Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
12.2.1. Brazil Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
12.2.1.1. Brazil Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
12.2.1.2. Brazil Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
12.2.1.3. Brazil Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.1.4. Brazil Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
12.2.2. Argentina Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
12.2.2.1. Argentina Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
12.2.2.2. Argentina Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
12.2.2.3. Argentina Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.2.4. Argentina Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
12.2.3. Rest of South America Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
12.2.3.1. Rest of South America Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
12.2.3.2. Rest of South America Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
12.2.3.3. Rest of South America Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
12.2.3.4. Rest of South America Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
Chapter 13. Middle East & Africa Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
13.1. Middle East & Africa Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
13.1.1. Market Deployment and projections, 2017 - 2028 (USD Million)
13.1.2. Middle East & Africa Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
13.1.3. Middle East & Africa Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
13.1.4. Middle East & Africa Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
13.1.5. Middle East & Africa Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
13.2. Middle East & Africa Lung Cancer Screening Software Market Overview, By Countries, 2017 - 2028 (USD Million)
13.2.1. GCC Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
13.2.1.1. GCC Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
13.2.1.2. GCC Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
13.2.1.3. GCC Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
13.2.1.4. GCC Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
13.2.2. South Africa Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
13.2.2.1. South Africa Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
13.2.2.2. South Africa Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
13.2.2.3. South Africa Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
13.2.2.4. South Africa Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
13.2.3. Rest of Middle East & Africa Lung Cancer Screening Software Market Overview, 2017 - 2028 (USD Million)
13.2.3.1. Rest of Middle East & Africa Lung Cancer Screening Software Market Overview, By Offering, 2017 - 2028 (USD Million)
13.2.3.2. Rest of Middle East & Africa Lung Cancer Screening Software Market Overview, By Deployment, 2017 - 2028 (USD Million)
13.2.3.3. Rest of Middle East & Africa Lung Cancer Screening Software Market Overview, By Application, 2017 - 2028 (USD Million)
13.2.3.4. Rest of Middle East & Africa Lung Cancer Screening Software Market Overview, By End-user, 2017 - 2028 (USD Million)
Chapter 14. Competitive Landscape
14.1. Competitive Environment, 2021
14.2. Strategic Framework
14.2.1. Partnership/Collaborations/Agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New Product Development
Chapter 15. Key Vendor Analysis
15.1. Koninklijke Philips N.V.
15.1.1. Business Overview
15.1.2. Product Benchmarking
15.1.3. Financial Data
15.1.4. Strategic Overview
15.1.5. Key Developments
15.1.6. SWOT Analysis
15.2. Siemens Healthineers AG
15.2.1. Business Overview
15.2.2. Product Benchmarking
15.2.3. Financial Data
15.2.4. Strategic Overview
15.2.5. Key Developments
15.2.6. SWOT Analysis
15.3. Thynk Health platform
15.3.1. Business Overview
15.3.2. Product Benchmarking
15.3.3. Financial Data
15.3.4. Strategic Overview
15.3.5. Key Developments
15.3.6. SWOT Analysis
15.4. Eon
15.4.1. Business Overview
15.4.2. Product Benchmarking
15.4.3. Financial Data
15.4.4. Strategic Overview
15.4.5. Key Developments
15.4.6. SWOT Analysis
15.5. Medtronic
15.5.1. Business Overview
15.5.2. Product Benchmarking
15.5.3. Financial Data
15.5.4. Strategic Overview
15.5.5. Key Developments
15.5.6. SWOT Analysis
15.6. Nuance Communications, Inc.
15.6.1. Business Overview
15.6.2. Product Benchmarking
15.6.3. Financial Data
15.6.4. Strategic Overview
15.6.5. Key Developments
15.6.6. SWOT Analysis
15.7. Volpara Health Limited
15.7.1. Business Overview
15.7.2. Product Benchmarking
15.7.3. Financial Data
15.7.4. Strategic Overview
15.7.5. Key Developments
15.7.6. SWOT Analysis
15.8. PenLung Solution
15.8.1. Business Overview
15.8.2. Product Benchmarking
15.8.3. Financial Data
15.8.4. Strategic Overview
15.8.5. Key Developments
15.8.6. SWOT Analysis
15.9. Magview
15.9.1. Business Overview
15.9.2. Product Benchmarking
15.9.3. Financial Data
15.9.4. Strategic Overview
15.9.5. Key Developments
15.9.6. SWOT Analysis
15.10. Others
Chapter 16. Future Outlook of the Market